Lionco Pharmaceuticals (603669) September 5 evening announcement, recently, the company's subsidiary Lionco Pharmaceuticals received the State Drug Administration issued “Cefzodoxime Sodium for Injection” supplemental application for approval of the notice of the drug, the drug through the generic quality and efficacy consistency evaluation.

As of the date of the announcement, the Company has invested RMB5.72 million in research and development for Cefozoxime Sodium for Injection. The drug is mainly used for lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and simple gonorrhea caused by sensitive bacteria.

According to IMS data, the China market sales of cefazoxime sodium for injection is 2,740 million yuan in 2023. According to the State Drug Administration (SDA), a total of 34 companies (including Lingkang Pharmaceuticals) have been approved to market cefzodoxime sodium for injection in China, of which 12 manufacturers (including Lingkang Pharmaceuticals) have passed the consistency evaluation.

According to the announcement, the passing of generic consistency evaluation of the drug is conducive to enhancing the market competitiveness and positively affecting the market sales of the drug, and also accumulates valuable experience for the company's subsequent products to carry out generic consistency evaluation.

In the first half of 2024, the company's operating income of 141 million yuan, an increase of 25.29%.

https://finance.eastmoney.com/a/202409063177571241.html